MAP3K5 and Hepatic fibrosis: Clinical trials using Pan-caspase inhibitor, ASK1 inhibitor, Dual NOX1/4 inhibitor, FXR agonist, CBP/β-catenin small molecule inhibitor, Hsp47 siRNA delivering lipid nanoparticle, LOXL2 specific monoclonal antibody, CCR2/CCR5 inhibitor, and Inhibitor of galectin-3 were conducted for management of liver fibrosis with various outcomes [102].